- Home
- MRT vs SKYE Comparison
MRT vs SKYE Comparison
Compare MRT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- SKYE
- Stock Information
- Founded
- MRT 2018
- SKYE 2012
- Country
- MRT Turkey
- SKYE United States
- Employees
- MRT N/A
- SKYE N/A
- Industry
- MRT Rental/Leasing Companies
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- SKYE Health Care
- Exchange
- MRT Nasdaq
- SKYE Nasdaq
- Market Cap
- MRT 117.0M
- SKYE 108.3M
- IPO Year
- MRT N/A
- SKYE N/A
- Fundamental
- Price
- MRT $1.94
- SKYE $4.17
- Analyst Decision
- MRT Buy
- SKYE Buy
- Analyst Count
- MRT 1
- SKYE 6
- Target Price
- MRT $0.90
- SKYE $18.67
- AVG Volume (30 Days)
- MRT 58.9K
- SKYE 165.6K
- Earning Date
- MRT 01-01-0001
- SKYE 11-07-2024
- Dividend Yield
- MRT N/A
- SKYE N/A
- EPS Growth
- MRT N/A
- SKYE N/A
- EPS
- MRT N/A
- SKYE N/A
- Revenue
- MRT $18,953,502.00
- SKYE N/A
- Revenue This Year
- MRT N/A
- SKYE N/A
- Revenue Next Year
- MRT N/A
- SKYE N/A
- P/E Ratio
- MRT N/A
- SKYE N/A
- Revenue Growth
- MRT N/A
- SKYE N/A
- 52 Week Low
- MRT $0.44
- SKYE $1.44
- 52 Week High
- MRT $2.73
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- MRT 43.03
- SKYE 35.87
- Support Level
- MRT $1.88
- SKYE $4.32
- Resistance Level
- MRT $1.98
- SKYE $5.67
- Average True Range (ATR)
- MRT 0.09
- SKYE 0.53
- MACD
- MRT -0.01
- SKYE -0.17
- Stochastic Oscillator
- MRT 35.66
- SKYE 0.57
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, operating a fleet of over 48,000 e-mopeds, e-bikes, and e-scooters, serviced by proprietary software systems and IoT infrastructure.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.